FDA Approves Tregzi: Precision-Engineered Treatment for Blood Cancer Patients

For decades, allogeneic hematopoietic stem cell transplantation (allo-HSCT) has served as a life-saving intervention for high-risk blood cancers such as acute leukemia and myelodysplastic syndrome. However, this procedure has historically presented a significant clinical trade-off: while it replaces a diseased immune system with donor cells to eradicate cancer, it often carries a high risk of chronic graft-versus-host disease (GVHD), where donor cells attack the recipient's healthy tissues.

On June 30, 2026, the landscape of transplant medicine evolved with the FDA’s approval of Tregzi (clinically known as Orca-T). Developed by Orca Biosystems, Inc., this is the first precision-engineered allogeneic regulatory T-cell immunotherapy. Rather than relying on unrefined cell grafts, Tregzi utilizes a calibrated cellular blueprint designed to balance anti-cancer immunity with immune tolerance.

From Reactive to Proactive: The Science of Precision Engineering

Traditionally, transplant medicine relied on reactive management, utilizing immunosuppressants to mitigate GVHD only after it manifested. Tregzi shifts this model toward a proactive approach. It consists of a precise mixture of hematopoietic stem and progenitor cells (HSPCs), regulatory T cells (Tregs), and conventional T cells (Tcon), all sourced from an 8/8 HLA-matched donor. The inclusion of regulatory T cells is the core differentiator, acting as natural "brakes" to ensure T-cells neutralize malignancy without damaging the patient’s healthy organs.

Comparison: Standard Transplant vs. Tregzi

Feature	Standard Stem Cell Transplant	Tregzi (Orca-T)
Composition	Unrefined donor graft	Precision-engineered cells (HSPC/Treg/Tcon)
Immune Strategy	Reactive (Manage GVHD post-onset)	Proactive (Engineered immune tolerance)
1-Year Chronic GVHD-Free Survival	38.4%	78%

Clinical Impact and the PRECISION-T Evidence

The FDA’s approval was based on the PRECISION-T clinical trial (N=187), which demonstrated that 78% of patients receiving Tregzi achieved chronic GVHD-free survival at one year, compared to 38.4% in the standard transplant control group. This improvement represents a significant advancement in long-term patient outcomes.

Safety Profile and Implementation

The safety profile of Tregzi remains consistent with standard stem cell transplantation. Infections were identified as the most common adverse event. Notably, the PRECISION-T trial reported no cases of graft failure and no severe infusion-related reactions.

The current Wholesale Acquisition Cost (WAC) for Tregzi is $428,000. Actual patient costs may vary based on insurance coverage, hospital-specific pricing, and manufacturer-supported patient assistance programs.